頭頸部扁平上皮癌治療薬の世界市場機会分析・予測

◆英語タイトル:OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2024
◆商品コード:GDHC054POA
◆発行会社(調査会社):GlobalData
◆発行日:2016年2月2日
◆ページ数:250
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD9,495 ⇒換算¥1,082,430見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD18,990 ⇒換算¥2,164,860見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD28,485 ⇒換算¥3,247,290見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、頭頸部扁平上皮癌治療薬の世界市場機会について調査・分析し、以下の構成でお届けいたします。
・イントロダクション
・頭頸部扁平上皮癌の概要:病因、病態生理、症状
・疫学:リスク要因、併存症、グローバル動向、予測方法、疫学的予測結果
・頭頸部扁平上皮癌治療薬市場の現状:診断、治療概要、臨床診療、主要な医薬品
・アンメット・ニーズ及び市場機会分析
・研究開発戦略
・パイプライン分析
・パイプラインの価値分析
【レポートの概要】

OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma – Opportunity Analysis and Forecast to 2024

Summary

The head and neck cancer (HNC) market is one currently dominated by generic chemotherapies, with little competition from branded therapies. The market landscape is set to undergo substantial growth between 2014 and 2024. The main drivers of growth will be an increase in the diagnosed HNC population and the launch of multiple premium-priced metastatic therapies, led by the class of immuno-oncology products. Historically, cytotoxic chemotherapies have comprised the bulk of the HNC market. Little competition between targeted therapies currently exists in the HNC market, leaving an area of considerable opportunity for interested new comers. Cisplatin is the standard treatment for HNC, due to its greater efficacy over other chemotherapy agents. However, as a cytotoxic agent, its use is limited by its high toxicity and poor safety profile.

The recent investment in HNC has seen a significant increase in research activity. The launch of new agents into the market and continued innovation in the developmental pipeline promises to produce a dynamic market over the forecast period.

Highlights

Key Questions Answered

- The HNC market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the HNC market?
- The late-stage HNC pipeline is varied and innovative. Will the late-stage drugs make a significant impact on the HNC market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
- The current HNC market is dominated by generic chemotherapy regimens with little branded competition. How will the advent of new targeted therapies change the treatment landscape for HNC? How will the drug treatment rate change over the next ten years? What are the key drivers and barriers to this change?

Key Findings

- New drug launches will increase competition and drive expansion of the HNC market. Over the forecast period, six pipeline drugs are expected to file for approval in HNC and the launch of these premium priced agents will drive significant increase in total drug sales in the 7MM.
- Immuno-oncology agents will be a major driver of treatment innovation. Results from ongoing clinical trials are highly anticipated by the medical community and combination therapies hold promise of greater treatment efficacy.
- The lack of predictive biomarkers in HNC will continue to pose an issue in adopting personalized treatment, and the increasing costs of new therapies will make this a more pressing issue.
- KOLs interviewed for this report expressed a need for better treatments in earlier lines of disease in order for treatments to be effective. There needs to be an emphasis on the prevention of disease recurrence, not just treating the recurrences after they occur.

Scope

- Overview of HNC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized HNC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HNC therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global HNC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global HNC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HNC therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Track drug sales in the global HNC therapeutics market from 2014-2024.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

【レポートの目次】

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 15
1.2 List of Figures 20
2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 23
2.3 Upcoming Related Reports 23
3 Disease Overview 24
3.1 Etiology and Pathophysiology 24
3.1.1 Etiology 24
3.1.2 Biomarkers 28
3.1.3 Pathophysiology 30
3.1.4 Clinical Staging 32
3.2 Diagnosis 43
3.3 Symptoms 44
3.4 Prognosis 46
3.4.1 Quality of Life 46
4 Epidemiology 48
4.1 Risk Factors and Comorbidities 48
4.2 Global and Historical Trends 49
4.2.1 Incidence 49
4.2.2 Relative Survival – 7MM 53
4.3 Forecast Methodology 55
4.3.1 Sources Used 62
4.3.2 Sources Not Used 65
4.3.3 Forecast Assumptions and Methods 65
4.4 Epidemiological Forecast for HNC and Thyroid Cancer (2014-2024) 67
4.4.1 Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer 67
4.4.2 Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers 68
4.4.3 Diagnosed Incident Cases of Larynx Cancer 70
4.4.4 Diagnosed Incident Cases of HNC 71
4.4.5 Diagnosed Incident Cases of Thyroid Cancer 73
4.4.6 Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer 74
4.4.7 Age-Specific Diagnosed Incident Cases of Larynx Cancer 76
4.4.8 Age-Specific Diagnosed Incident Cases of Thyroid Cancer 78
4.4.9 Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer 80
4.4.10 Sex-Specific Diagnosed Incident Cases of Larynx Cancer 82
4.4.11 Sex-Specific Diagnosed Incident Cases of Thyroid Cancer 84
4.4.12 Age-Standardized Diagnosed Incidence of Lip, Oral Cavity, and Pharynx Cancer 86
4.4.13 Age-Standardized Diagnosed Incidence of Larynx Cancer 87
4.4.14 Age-Standardized Diagnosed Incidence of Thyroid Cancer 88
4.4.15 Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Clinical Stage at Diagnosis 89
4.4.16 Diagnosed Incident Cases of Larynx Cancer by Clinical Stage at Diagnosis 90
4.4.17 Diagnosed Incident Cases of Thyroid Cancer by Clinical Stage at Diagnosis 91
4.4.18 Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Histology Distribution 92
4.4.19 Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers by Histology Distribution 93
4.4.20 Diagnosed Incident Cases of Larynx Cancer by Histology Distribution 94
4.4.21 Diagnosed Incident Cases of Thyroid Cancer by Histology Distribution 95
4.4.22 Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer 96
4.4.23 Five-Year Diagnosed Prevalent Cases of Larynx Cancer 98
4.4.24 Five-Year Diagnosed Prevalent Cases of Thyroid Cancer 99
4.5 Discussion 101
4.5.1 Epidemiological Forecast Insight 101
4.5.2 Limitations of the Analysis 101
4.5.3 Strengths of the Analysis 102
5 Current Treatment Options 103
5.1 Overview 103
5.2 Product Profiles 106
5.2.1 Erbitux (cetuximab) 106
5.2.2 TS-1 (tegafur + gimeracil + oteracil) 115
5.3 Standard of Care Chemotherapy Review 121
5.3.1 Cisplatin 121
5.3.2 Docetaxel 123
5.3.3 Fluorouracil (5-FU) 125
5.3.4 Methotrexate 125
6 Unmet Needs Assessment and Opportunity Analysis 126
6.1 Overview 126
6.2 Unmet Needs Analysis 127
6.2.1 Treatments for Recurrent and Metastatic Disease 127
6.2.2 Treatments for Locally Advanced Head and Neck Cancers 130
6.2.3 Treatments for HPV-negative Disease 132
6.2.4 Management of Co-morbidities and Adverse Events Arising from Traditional Therapy 133
6.2.5 Predictive Biomarkers to Guide and Improve the Current Treatments in Use 135
6.2.6 Investment in Non-squamous Cell Carcinomas of the Head and Neck 137
7 R&D Strategies 139
7.1 Overview 139
7.1.1 Emergence of Immuno-Oncology Agents in the Late-Phase Pipeline 139
7.1.2 Kinase Inhibitors in the Early Stage Pipeline 140
7.1.3 Therapeutic HPV Vaccines for HPV-Positive Patients 142
7.2 Clinical Trial Design 143
7.2.1 Overall Patient Survival Most Important Outcome for Treatment 145
7.2.2 Majority of New Drugs Targeting rmHNSCC 146
7.2.3 Lack of Consistency in Comparator in the HNSCC Trials 147
8 Pipeline Assessment 149
8.1 Overview 149
8.2 Drugs in Late-Stage Clinical Development 149
8.2.1 Javlor (vinflunine) 150
8.2.2 Gilotrif (afatinib) 156
8.2.3 Multikine (leukocyte interleukin) 163
8.2.4 Nimoral (nimorazole) 169
8.2.5 Vectibix (panitumumab) 170
8.2.6 Reolysin (pelareorep) 171
8.3 Immune Checkpoint Inhibitors 172
8.3.1 Overview 172
8.3.2 Opdivo (nivolumab) 174
8.3.3 Keytruda (pembrolizumab) 180
8.3.4 Durvalumab (MEDI4736) 188
8.4 Innovative Early-stage Approaches 194
8.4.1 Therapeutic Cancer Vaccines 196
8.4.2 Kinase Inhibitors for Prevention of Downstream Signaling 196
8.4.3 Virus-based Therapies for the Treatment of Solid Tumors 197
9 Pipeline Valuation Analysis 198
9.1 Clinical Benchmark of Key Pipeline Drugs 198
9.2 Commercial Benchmark of Key Pipeline Drugs 201
9.3 Competitive Assessment 203
9.4 Top-Line Ten Year Forecast 204
9.4.1 US 207
9.4.2 5EU 208
9.4.3 Japan 209
10 Appendix 210
10.1 Bibliography 210
10.2 Abbreviations 230
10.3 Methodology 234
10.4 Forecasting Methodology 234
10.4.1 Diagnosed Head and Neck Cancer patients 234
10.4.2 Percent Drug-treated Patients 234
10.4.3 Drugs Included in Each Therapeutic Class 235
10.4.4 Launch and Patent Expiry Dates 235
10.4.5 General Pricing Assumptions 236
10.4.6 Individual Drug Assumptions 237
10.4.7 Generic Erosion 240
10.4.8 Pricing of Pipeline Agents 240
10.5 Physicians and Specialists Included in this Study 244
10.6 About the Authors 245
10.6.1 Author 245
10.6.2 Reviewer 245
10.6.3 Therapy Area Director 245
10.6.4 Epidemiologist 246
10.6.5 Reviewers 246
10.6.6 Global Director of Therapy Analysis and Epidemiology 247
10.6.7 Global Head of Healthcare 248
10.7 About GlobalData 249
10.8 Disclaimer 249

1.1 List of Tables
Table 1: ICD-10 Codes used to classify Head and Neck Cancers 28
Table 2: Head and Neck Cancer Locations and Their Clinically Defined Locations 31
Table 3: TNM Classification of Lip, Oral Cavity, and Oropharyngeal Cancers 33
Table 4: TNM Classification of the Larynx 34
Table 5: TNM Classification of the Hypopharynx 36
Table 6: TNM Classification of Nasal Cavity and Paranasal Sinus Cancers 37
Table 7: TNM Classification of Salivary Gland Cancers 39
Table 8: TNM Classification of Nasopharyngeal Cancers 40
Table 9: TNM Classification of Thyroid Gland Cancers 41
Table 10: Stage Grouping for Head and Neck Cancer (Excluding Nasopharyngeal and Thyroid Cancer) 42
Table 11: Stage Grouping for Nasopharyngeal Cancer 42
Table 12: Stage Grouping of Thyroid Gland Cancers 43
Table 13: Symptoms of Head and Neck Squamous Cell Carcinoma 45
Table 14: Risk Factors for HNC 49
Table 15: Trends in the Age-Adjusted Incidence of Lip, Oral Cavity, and Pharynx Cancer in the 7MM, All Ages, 1998-2007 50
Table 16: Trends in the Age-Adjusted Incidence of Larynx Cancer in the 7MM, All Ages, 1998-2007 51
Table 17: Trends in the Age-Adjusted Incidence of Thyroid Cancer in the 7MM, All Ages, 1998-2007 52
Table 18: Trends in the Five-Year Relative Survival (%) of HNC and Thyroid Cancer in the 7MM, Both Sexes, 1993-2007 54
Table 19: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer 55
Table 20: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Larynx Cancer 56
Table 21: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Nose, Sinuses, and Related Cancer 57
Table 22: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Thyroid Cancer 58
Table 23: 7MM, Sources of Epidemiological Data Used for the Forecast for the Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer 58
Table 24: 7MM, Sources of Epidemiological Data Used for the Forecast for the Five-Year Diagnosed Prevalent Cases of Larynx Cancer 59
Table 25: 7MM, Sources of Epidemiological Data Used for the Forecast for the Five-Year Diagnosed Prevalent Cases of Thyroid Cancer 59
Table 26: 7MM, Sources of Epidemiological Data Used for the Segmentation of Diagnosed Incident Cases of HNC (Excluding Nose, Sinuses, and Related Cancers) and Thyroid Cancer by Clinical Stage at Diagnosis 60
Table 27: 7MM, Sources of Epidemiological Data Used for the Segmentation of the Diagnosed Incident Cases HNC and Thyroid Cancer by Histology Distribution 61
Table 28: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, All Ages, N, 2014-2024 68
Table 29: 7MM, Diagnosed Incident Cases of Nose, Sinuses, and Related Cancer, Both Sexes, All Ages, N, 2014-2024 69
Table 30: 7MM, Diagnosed Incident Cases of Larynx Cancer, Both Sexes, All Ages, N, 2014-2024 71
Table 31: 7MM, Diagnosed Incident Cases of HNC, Both Sexes, All Ages, N, 2014-2024 72
Table 32: 7MM, Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, All Ages, N, 2014-2024 74
Table 33: 7MM, Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, N (Row %), 2014 75
Table 34: 7MM, Age-Specific Diagnosed Incident Cases of Larynx Cancer, Both Sexes, N (Row %), 2014 77
Table 35: 7MM, Age-Specific Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, N (Row %), 2014 79
Table 36: 7MM, Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, N (Row %), 2014 81
Table 37: 7MM, Sex-Specific Diagnosed Incident Cases of Larynx Cancer, All Ages, N (Row %), 2014 83
Table 38: 7MM, Sex-Specific Diagnosed Incident Cases of Thyroid Cancer, All Ages, N (Row %), 2014 85
Table 39: 7MM, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, Both Sexes, N, 2014-2024 97
Table 40: 7MM, Five-Year Diagnosed Prevalent Cases of Larynx Cancer, All Ages, Both Sexes, N, 2014-2024 98
Table 41: 7MM, Five-Year Diagnosed Prevalent Cases of Thyroid Cancer, All Ages, Both Sexes, N, 2014-2024 100
Table 42: Leading Treatments for Head and Neck Cancers 104
Table 43: Product Profile - Erbitux 107
Table 44: Efficacy of Erbitux with Cisplatin and 5-FU in rmHNSCC Patients, in a Phase III, Randomized Open-Label Trial. 110
Table 45: Efficacy of Erbitux with Radiotherapy in Locally Advanced HNSCC in Phase III, Randomized Open-Label Trial. 111
Table 46: Safety of Erbitux with Cisplatin and 5-FU Chemotherapy in rmHNSCC 113
Table 47: Erbitux SWOT Analysis 114
Table 48: Global Sales Forecast ($m) for Erbtiux, 2014-2024 115
Table 49: Product Profile - TS-1 116
Table 50: Safety of TS-1 Monotherapy in Patients with rmHNSCC 119
Table 51: TS-1 SWOT Analysis 120
Table 52: Global Sales Forecast ($m) for TS-1, 2014-2024 121
Table 53: Overall Unmet Needs - Current Level of Attainment 127
Table 54: Phase III Pipeline Clinical Trial Design 144
Table 55: Head and Neck Squamous Cell Carcinoma - Late Stage Pipeline, 2015 150
Table 56: Product Profile - Javlor 151
Table 57: Efficacy of Javlor with Methotrexate in rmHNSCC from Single Arm, Phase I Dose Finding Trial (ASCO 2015) 154
Table 58: Safety of Javlor with Methotrexate in rmHNSCC from a Single Arm, Phase I Dose Finding Trial (ASCO 2015) 155
Table 59: Javlor SWOT Analysis 155
Table 60: Global Sales Forecast ($m) for Javlor, 2014-2024 156
Table 61: Product Profile - Gilotrif 157
Table 62: Efficacy of Gilotrif with Methotrexate in rmHNSCC 160
Table 63: Safety of Gilotrif with Methotrxate in rmHNSCC (NCT01345682) 161
Table 64: Gilotrif SWOT Analysis 162
Table 65: Global Sales Forecast ($m) for Gilotrif, 2014-2024 163
Table 66: Product Profile - Multikine (interleukin injection) 164
Table 67: Disclosed Components of Multikine - Major Cytokines and Other Cellular Products 165
Table 68: Multikine SWOT Analysis 168
Table 69: Global Sales Forecast ($m) for Multikine, 2014-2024 169
Table 70: Product Profile - Opdivo 174
Table 71: Safety of dacarbazine v. Opdivo in advanced melanoma (checkmate-066) 178
Table 72: Opdivo SWOT Analysis 179
Table 73: Global Sales Forecast ($m) for Opdivo, 2014-2024 180
Table 74: Product Profile - Keytruda 181
Table 75: Safety of Investigator’s Chemotherapy versus Keytruda in Ipilimumab-Refractory Melanoma (KEYNOTE-002) 186
Table 76: Keytruda SWOT Analysis 187
Table 77: Global Sales Forecast ($m) for Keytruda, 2014-2024 188
Table 78: Product Profile - Durvalumab 189
Table 79: Safety of Durvalumab Single Agent in rmHNSCC from Single Arm, Phase I Dose Finding Trial (ASCO 2015) 193
Table 80: MEDI4736 SWOT Analysis 193
Table 81: Global Sales Forecast ($m) for durvalumab, 2014-2024 194
Table 82: Select early-stage pipeline products in HNSCC 195
Table 83: Clinical Benchmark of Key Pipeline Drugs - Locally advanced HNSCC 198
Table 84: Clinical Benchmark of Key Pipeline Drugs - rmHNSCC 199
Table 85: Commercial Benchmark of Key Pipeline Drugs 201
Table 86: Top Line Sales Forecasts ($million USD) for HNSCC, 2014-2024 205
Table 87: Key Events Impacting Sales for HNSCC 206
Table 88: HNSCC Market - Drivers and Barriers, 2014-2024 207
Table 89: Key Launch Dates, 2014-2024 235
Table 90: Key Patent Expiries, 2014-2024 235

1.2 List of Figures
Figure 1: Anatomical Sites of Head and Neck Cancers. 27
Figure 2: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, All Ages, N, 2014-2024 68
Figure 3: 7MM, Diagnosed Incident Cases of Nose, Sinuses, and Related Cancer, Both Sexes, All Ages, N, 2014-2024 70
Figure 4: 7MM, Diagnosed Incident Cases of Larynx Cancer, Both Sexes, All Ages, N, 2014-2024 71
Figure 5: 7MM, Diagnosed Incident Cases of HNC, Both Sexes, All Ages, N, 2014-2024 73
Figure 6: 7MM, Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, All Ages, N, 2014-2024 74
Figure 7: 7MM, Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, N, 2014 76
Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of Larynx Cancer, Both Sexes, N, 2014 78
Figure 9: 7MM, Age-Specific Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, N, 2014 80
Figure 10: 7MM, Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, N, 2014 82
Figure 11: 7MM, Sex-Specific Diagnosed Incident Cases of Larynx Cancer, All Ages, N, 2014 84
Figure 12: 7MM, Sex-Specific Diagnosed Incident Cases of Thyroid Cancer, All Ages, N, 2014 86
Figure 13: 7MM, Age-Standardized Diagnosed Incidence Cases of Lip, Oral Cavity, and Pharynx Cancer (Cases per 100,000 Population), All Ages, by Sex, 2014 87
Figure 14: 7MM, Age-Standardized Diagnosed Incidence Cases of Larynx Cancer (Cases per 100,000 Population), All Ages, by Sex, 2014 88
Figure 15: 7MM, Age-Standardized Diagnosed Incidence Cases of Thyroid Cancer (Cases per 100,000 Population), All Ages, by Sex, 2014 89
Figure 16: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014 90
Figure 17: 7MM, Diagnosed Incident Cases of Larynx Cancer by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014 91
Figure 18: 7MM, Diagnosed Incident Cases of Thyroid Cancer by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014 92
Figure 19: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Histology Distribution, All Ages, Both Sexes, N, 2014 93
Figure 20: 7MM, Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers by Histology Distribution, All Ages, Both Sexes, N, 2014 94
Figure 21: 7MM, Diagnosed Incident Cases of Larynx Cancer by Histology Distribution, All Ages, Both Sexes, N, 2014 95
Figure 22: 7MM, Diagnosed Incident Cases of Thyroid Cancer by Histology Distribution, All Ages, Both Sexes, N, 2014 96
Figure 23: 7MM, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, Both Sexes, N, 2014-2024 97
Figure 24: 7MM, Five-Year Diagnosed Prevalent Cases of Larynx Cancer, All Ages, Both Sexes, N, 2014-2024 99
Figure 25: 7MM, Five-Year Diagnosed Prevalent Cases of Thyroid Cancer, All Ages, Both Sexes, N, 2014-2024 100
Figure 26: Treatment Overview in HNSCC Patients 105
Figure 27: Treatment Overview in Nasopharyngeal Carcinoma Patients 106
Figure 28: Javlor’s Development in HNSCC 153
Figure 29: Gilotrif’s Development in HNSCC 160
Figure 30: Multikine’s Development in HNSCC 166
Figure 31: Opdivo’s Development in HNSCC 176
Figure 32: Keytruda’s Development in HNSCC 184
Figure 33: Durvalumab’s Development in HNSCC 191
Figure 34: Competitive Assessment of Marketed and Pipeline HNSCC Agents, 2014-2024 204

【掲載企業】

Advaxis, Inc.
Amgen
AstraZeneca
Azanta A/S
Boehringer Ingelheim
Bristol-Myers Squibb
CEL-SCI
Curis Pharmaceutical
Eli Lilly
F. Hoffman La-Roche
GlaxoSmithKline
Glycotope
Marsala Biotech
Merck & Co. (MSD)
Merck KGaA
Nordic Pharma
Oncolytics Biotech
Ono Pharmaceuticals
Pfizer
Pierre Fabre Medicament
Taiho Pharmaceutical

★調査レポート[頭頸部扁平上皮癌治療薬の世界市場機会分析・予測]販売に関する免責事項
★調査レポート[頭頸部扁平上皮癌治療薬の世界市場機会分析・予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆